

Extent of resection, MGMT promoter methylation status and tumor location independently predict progression-free survival in adult sporadic pilocytic astrocytoma

Christine Jungk, Annekathrin Reinhardt, Rolf Warta, David Capper, Andreas von Deimling, Christel Herold-Mende and Andreas Unterberg

Table 1. Institutional Cohort of Adult Pilocytic Astrocytomas (n = 58): Demographic, Tumor, Molecular and Treatment Characteristics and Patient Outcome.

No	Sex ^a	Age (years)	Tumor characteristics			Treatment at 1st diagnosis				Outcome			
			Infra-tentorial	Location ^b	MGMTmeth	EOR	Surgical Complications ^c	Radiotherapy	Others	No. of Relapses	PFS (months)	Follow-up (months)	Death
1	0	21	1	2	1	STR	Cranial nerve palsy	0	0	2	37	75	1
2	0	17	0	3	0	STR	NA	0	0	2	61	259	0
3	1	42	0	3	0	Biopsy	0	0	TMZ	2	46	210	0
4	0	39	0	1	0	STR	NA	0	0	1	135	211	0
5	1	30	1	3	0	GTR	Hemiparesis	0	0	1	59	186	0
6	0	61	1	3	0	GTR	0	0	0		153	153	0
7	1	20	0	1	0	Biopsy	0	0	0		143	143	0
8	0	26	0	3	0	GTR	0	0	0		90	129	0
9	1	18	1	3	0	GTR	Dysphagia	0	0		128	128	0
10	1	24	1	1	0	GTR	0	0	0		101	130	0
11	0	31	0	1	0	Biopsy	0	0	0	2	10	117	0
12	1	28	1	3	0	GTR	CSF fistula	0	0		96	114	0
13	1	20	1	3	0	GTR	CSF fistula	0	0		26	111	0
14	1	51	0	3	1	GTR	0	0	0		97	109	0
15	0	18	0	3	0	STR	0	0	0	1	113	119	0
16	0	23	1	1	0	STR	Dysphagia, CSF shunt	0	0		109	109	0
17	0	36	0	3	0	GTR	0	0	0		44	103	0
18	1	24	1	1	0	GTR	0	0	0		18	102	0
19	1	18	1	3	0	GTR	Ataxia	0	0		97	97	0
20	0	65	1	3	0	GTR	Dysphagia, ataxia	0	0		17	100	0
21	0	66	1	1	1	STR	0	0	0		86	87	0
22	0	36	1	1	0	STR	Cranial nerve palsy	0	0	1	15	105	0
23	0	56	0	3	0	GTR	0	0	0		61	95	0
24	1	27	1	3	0	GTR	0	0	0		75	78	0
25	1	60	1	2	0	GTR	0	0	0		71	83	0
26	0	19	0	0	0	GTR	0	0	0	1	59	83	0
27	0	31	1	2	1	STR	Re-bleeding	0	0		64	80	0
28	0	24	0	1	0	STR	0	0	Hyperthermia		85	87	0

29	0	20	0	3	1	GTR	0	0	0	1	23	69	0
30	1	23	0	3	0	GTR	0	0	0		11	74	0
31	0	44	1	1	0	GTR	CSF fistula	0	0		6	68	0
32	0	25	0	3	NA	GTR	0	0	0		66	66	0
33	1	30	1	1	0	GTR	CSF shunt	0	0		65	65	0
34	1	31	0	3	0	GTR	0	0	0		69	70	0
35	1	23	1	3	0	GTR	0	0	0		61	61	0
36	0	18	1	3	0	Biopsy	0	SRS (13 Gy)	0	2	14	67	0
37	0	24	0	1	0	Biopsy	0	FRT (protons, 52,2 GyE)	0		61	61	0
38	1	24	0	1	1	Biopsy	0	0	0	1	12	59	0
39	1	52	0	3	1	Biopsy	0	FRT (protons, 54 GyE)	0	2	10	52	0
40	1	48	1	3	0	GTR	0	0	0		48	48	0
41	1	51	0	3	0	STR	0	0	0	1	55	55	0
42	0	29	1	3	0	GTR	0	0	0		36	47	0
43	1	20	1	1	0	GTR	CSF fistula	0	0		45	45	0
44	1	57	0	1	0	Biopsy	0	FRT (photons, 54 Gy)	0		7	42	0
45	0	28	1	1	0	GTR	CSF shunt	0	0		49	49	0
46	1	32	1	1	0	GTR	0	0	0		44	44	0
47	1	64	0	3	1	GTR	0	0	0	1	33	38	0
48	1	31	0	1	0	GTR	0	0	0		33	45	0
49	1	22	1	2	0	GTR	0	0	0		38	38	0
50	0	22	1	1	0	GTR	0	0	0		37	37	0
51	0	19	0	3	0	GTR	0	0	0		25	25	0
52	0	35	1	1	0	GTR	0	0	0		30	30	0
53	1	51	1	1	0	GTR	0	0	0		26	26	0
54	0	36	0	3	0	GTR	Wound debridement	0	0		18	18	0
55	1	31	1	3	0	GTR	0	0	0		12	13	0
56	1	30	0	3	0	GTR	0	0	0		2	3	0
57	1	37	1	2	0	GTR	0	0	0		3	3	0
58	0	33	0	1	0	STR	0	0	0	1	12	12	0

Sex ^a: (1) female, (0) male. Location ^b: (1) midline, (2) CPA, (3) hemisphere. Surgical Complications: newly acquired neurological deficits persisting > 6 months after surgery. GTR: gross total resection; STR: subtotal resection; CSF: craniospinal fluid; SRS: stereotactic radiosurgery; FRT: fractionated radiotherapy; Gy: Gray; TMZ: temozolomide; PFS: progression-free survival; NA: not available.